3. Patient Case 1

5. Patient Case 1: PET/CT Scan

6. Patient Case 1: Disease Stage

7. Techniques for Diagnosis of Lung Cancer

8. Use of EBUS Cytologic Material for Molecular Diagnosis of Lung Cancer

9. Histology in NSCLC

10. Lung Cancer Pathology: Non-Small Cell Carcinoma and Small Tissue Specimens

11. EBUS and Genotyping: Navani Study

12. EBUS and Genotyping: Navani Study (cont)

15. Cisplatin/Pemetrexed vs Cisplatin/ Gemcitabine: First-line Therapy

18. Patient Case 1: Treatment

19. Patient Case 1: Maintenance or Not?

20. IFCT-GFPC 0502: Gemcitabine vs Erlotinib vs Observation as Maintenance

21. IFCT-GFPC 0502: Treatment Outcomes

24. SATURN Trial: PFS and OS for All Patients (ITT)

25. SATURN Trial: PFS and OS by Induction Response

27. Patient Case 1: Progression

29. Forest Plot of Survival by Subsets

35. Types of Gene Mutation Assays

36. Positions of Mutations Detected in EGFR Tyrosine Kinase Domain in NSCLC

37. Tyrosine Kinase Inhibitors

38. Compilation of EGFR TKI Studies

39. IPASS Study: Prospective Clinical Selection/Retrospective Molecular Selection

40. Objective Response Rate in Patients Positive and Negative for EGFR Mutation

41. Comparison of PFS by Mutation Status Within Treatment Arms

42. HRQoL and Symptom Improvement by EGFR Mutation Status (EFQ)

43. Patient Case 2: Progression

44. Patient Case 2: Treatment

45. Patient Treated With Gefitinib for Exon 19 Mutation-Positive Lung Cancer Since 2005

46. Patient Case 2: Progression (cont)

47. Patient Case 2: Treatment (cont)

49. Importance of Working Together

50. Thank you for participating in this activity.